BridgeMD
eGPA and local inflammation within the ENT area
EU CTIS ID: 2023-508029-28-00
What this study is testing
In eGPA patients treatment with mepolizumab restores changes of the nasal microbiome healthy control phenotype
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- >18 years of age
- Able to give informed consent
- In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan
- In Severe asthma group: clinical diagnosis of asthma with FEV1 <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml)
- In eGPA group: Fulfilling the 2022 ACR/EULAR criteria for eGPA (Wechsler et al., 2017)
- In GPA group: fulfilling the ACR/EULAR GPA criteria (Robson et al., 2022)
You likely can't join if
- Unable to give informed consent
- Active smoking < (less than) 6 months from baseline visit
- Pregnant or breastfeeding woman
- In CRSwNP group: current use of asthma medication, eGPA
- In healthy controls: chronic use of local anti-inflammtory agents
- In healthy controls: use of immunosuppressive medication
See the full eligibility criteria
- >18 years of age
- Able to give informed consent
- In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan
- In Severe asthma group: clinical diagnosis of asthma with FEV1 <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml)
- In eGPA group: Fulfilling the 2022 ACR/EULAR criteria for eGPA (Wechsler et al., 2017)
- In GPA group: fulfilling the ACR/EULAR GPA criteria (Robson et al., 2022)
- In healthy controls: absence of asthma symptoms, no bronchial hyperresponsiveness
- Unable to give informed consent
- Active smoking < (less than) 6 months from baseline visit
- Pregnant or breastfeeding woman
- In CRSwNP group: current use of asthma medication, eGPA
- In healthy controls: chronic use of local anti-inflammtory agents
- In healthy controls: use of immunosuppressive medication
- In healthy controls: use of antibiotics within the last month (before start study/screening/)
- concomitant use of dupilumab within 6 months of baseline visit
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.